CDC Panel Updates Hepatitis B Vaccine Timing for Newborns
ACIP votes to delay the first hepatitis B vaccine dose for most newborns, signaling a shift in vaccination timing and sparking policy debates.
ACIP votes to delay the first hepatitis B vaccine dose for most newborns, signaling a shift in vaccination timing and sparking policy debates.
Examines the CDC's shift under RFK Jr. toward individual vaccine decisions and the controversy over the hepatitis B birth vaccine.
Trump urges a CDC-backed review of the U.S. vaccine schedule, weighing international practices to balance coverage with public health.
CDC shifts hepatitis B birth dose to conditional on maternal status, signaling more individualized vaccine decisions.
Vaccination gaps rise across the US as nonmedical exemptions grow and policy changes reshape immunization strategies.
The CDC shifts hepatitis B birth-dose guidance to individualized decisions, highlighting clinician-family discussions and ongoing monitoring.
Evidence shows vaccines are safe and effective, debunking concerns and highlighting benefits for children and communities.
ACIP weighs ending universal hepatitis B vaccination at birth while reviewing safety and transparency in childhood immunization policy.
Explores why young adults face vaccination decisions, barriers to uptake, and how education and access boost adult immunization.